Schering-Plough Announces Asenapine NDA Accepted for Filing by th...(ctors product availability patent and ot...),Health

Date:11/25/2007

ctors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details and a discussion of risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in Schering-Plough's third quarter 2007 10-Q.

References

1. National Institute of Mental Health. Available online at:

http://www.nimh.nih.gov/publicat/bipolar.cfm

2. Depression and Bipolar Support Alliance (DBSA). Bipolar Disorder

Statistics, accessed on May 10, 2007. http://www.dbsalliance.org/site/PageServer?pagename=about_statistics_bipolar

3. World Health Organization. WHO European Ministry Conference on Mental

Health. Available online at:

http://www.euro.who.int/document/MNH/emnhqa.pdf.

Accessed on October 2, 2007

4. National Alliance on Mental Health. Understanding Bipolar Disorder and

Recovery. Available online at: http://www.nami.org/Template.cfm?Section=bipolar_disorder&template=/ContentManagement/ContentDisplay.cfm&ContentID=44951

5. Perlis RH, Ostacher MJ, Patel JK. Predictors of Recurrence in Bipolar

Disorder: Primary Outcomes from the Systemic Treatment Enhancement

Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163:210-
224.

6. World Health Organ
'/>"/>

SOURCE Schering-Plough Corporation Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results